Mengke Pharmaceutical (688373.SH) disclosed its 2023 annual report. The company achieved an operating income of 90 during the reporting period...
According to the Zhitong Finance App, Mengke Pharmaceutical (688373.SH) disclosed its 2023 annual report. The company achieved operating revenue of 907.764 million yuan during the reporting period, an increase of 88.31% over the previous year. The net loss attributable to shareholders of listed companies was 421 million yuan, and the net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 454 million yuan. The loss increased year-on-year.
According to reports, the company is an innovative drug company focusing on treating infectious diseases and is listed using the fifth set of standards. During the reporting period, the company already sold its core product, contizolamide tablets, and clinical trials of many other products under development were being promoted domestically and internationally; at the same time, the company continued to expand its R&D team and academic promotion team. Since operating income does not yet cover related R&D investment and other expenses, the company's net profit in 2023, which is attributable to the owner of the parent company after deducting non-recurring profit and loss, was negative, and profit has not yet been realized.